Table 1.
Characteristics of studies included in the meta-analysis
| Study | Year | Country | Ethnicity | Duration of study conducted | Follow-up duration (months) | Age (years)a | Pathological type | Pathological subtypes, n (%) | No. of patientsb | No. of stage I/II | No. of stage III/IV | Outcome | Cutoff value | Method of obtaining cutoff | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||||||
| Eo et al7 | 2016 | Korea | Asian | 2006.1– 2013.12 | NA | 54 (14–84) | EOC | Serous: 132 (56.4) Mucinous: 35 (15.0) Clear cell: 35 (15.0) Endometrioid: 21 (10.0) Mixed epithelial: 5 (2.1) Others: 6 (2.6) |
234 | 97 | 137 | OS and PFS | 2.07 | ROC curve | 6 |
| Sun and Song21 | 2016 | China | Asian | 2006.2– 2014.4 | NA | 55 (17–84) | EOC | Serous: 103 (54.5) Others: 86 (45.5) |
189 | 78 | 111 | OS and PFS | 1.85 | ROC curve | 6 |
| Wang et al24 | 2016 | China | Asian | 2000.1– 2013.12 | NA | 56.1±10.2 | OC | Serous: 214 (89.2) Mucinous: 22 (9.2) Endometrioid: 2 (0.8) Clear cell: 2 (0.8) |
240 | 59 | 181 | OS | 3.949 | ROC curve | 6 |
| Kwon et al9 | 2017 | Korea | Asian | 2009.4– 2012.6 2000–2010 |
NA | 70 (65–85) | EOC | Serous: 33 (78.6) Non-serous: 9 (21.4) |
42 | 0 | 42 | OS and PFS | 3.63 | ROC curve | 6 |
| Li et al10 | 2017 | USA | Caucasian | 2000–2010 | 49.5 (0.1–175.3) | 63 (28–93) | EOC | High-grade serous: 525 (80.3) Low-grade serous: 4 (0.6) Endometrioid: 71 (10.9) Clear cell: 37 (5.7) Mucinous: 17 (2.6) |
654 | 121 | 533 | OS and PFS | 2.22 | ROC curve | 8 |
| Xiang et al11 | 2017 | China | Asian | 2011.1– 2016.3 2007.1– 2015.12 |
23.6 (0.77–69.4) | 53.3±13.6 (20–82) | OC | Serous: 87 (65.4) Mucinous: 14 (10.5) Endometrioid: 10 (7.5) Clear cell: 5 (3.8) Others: 17 (12.8) |
124 | 64 | 69 | OS | 4.35 | ROC curve | 6 |
| Zhang et al5 | 2017 | China | Asian | 2007.1– 2015.12 | NA | 50 (24–76) | OC | Serous: 123 (51.9) Non-serous: 114 (36.3) |
237 | 67 | 170 | OS and PFS | 3.82 | NA | 5 |
| Zhu et al6 | 2017 | China | Asian | 2008.6– 2015.12 | 38 (5–103) | 55 (30–70) | EOC | Serous: 484 (72.0) Non-serous: 188 (28.0) |
672 | 0 | 672 | OS and PFS | 3.45 | ROC curve | 7 |
| Tang et al22 | 2017 | China | Asian | 2005.1– 2015.1 | 46 (2–120) | 52.2±12.0 | EOC | Serous: 146 (68.2) Non-serous: 68 (31.8) |
214 | 99 | 115 | OS | 3.85 | ROC curve | 7 |
| Tian23 | 2017 | China | Asian | 2009.1– 2011.7 | 58 (2–60) | 54 (14–76) | EOC | Serous: 166 (62.2) Mucinous: 21 (7.9) Endometrioid: 65 (24.3) Clear cell: 14 (5.2) Others: 1 (0.4) |
267 | 86 | 181 | OS and PFS | 3.09 (OS) 2.07 (PFS) | ROC curve | 7 |
| Yang and Lo25 | 2017 | China | Asian | 2005.1–2011.5 | 37 (1–112) | 54 (22–78) | EOC | Serous: 206 (56.6) Mucinous: 111 (30.5) Endometrioid: 23 (6.3) Others: 24 (6.6) |
364 | 52 | 312 | OS and PFS | 3.84 | ROC curve | 7 |
| Kwon et al8 | 2018 | Korea | Asian | 2005.1–2011.5 | NA | 50 (24–77) | OCCC | OCCC: 109 (100) | 109 | 64 | 45 | OS and PFS | 4.2 | ROC curve | 6 |
Notes:
a
Mean, median (range) of age at baseline.
b
Number of patients at baseline.
Abbreviations: EOC, epithelial ovarian cancer; NA, not available; NOS, Newcastle–Ottawa Scale; OC, ovarian cancer; OCCC, ovarian clear cell carcinoma; OS, overall survival; PFS, progression-free survival; ROC, receiver-operator characteristic.